Related references
Note: Only part of the references are listed.Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40
Yan Yang et al.
BLOOD (2012)
Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy
P. J. Shami et al.
LEUKEMIA (2012)
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results
P. D. le Coutre et al.
LEUKEMIA (2012)
Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia
Su Jin Lee et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS
Stephane Bouchet et al.
CLINICA CHIMICA ACTA (2011)
Stabilin-1/CLEVER-1, a type 2 macrophage marker, is an adhesion and scavenging molecule on human placental macrophages
Senthil Palani et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia
D. Bixby et al.
LEUKEMIA (2011)
Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation
A. Kreutzman et al.
LEUKEMIA (2011)
A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors
John J. Powers et al.
LEUKEMIA & LYMPHOMA (2011)
Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib
Jason N. Valent et al.
LEUKEMIA RESEARCH (2011)
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
Theonie Anastassiadis et al.
NATURE BIOTECHNOLOGY (2011)
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis et al.
NATURE BIOTECHNOLOGY (2011)
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
Vinod P. Balachandran et al.
NATURE MEDICINE (2011)
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
Jan K. Hennigs et al.
BMC PULMONARY MEDICINE (2011)
Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy
Anna Kreutzman et al.
BLOOD (2010)
Latent Cytomegalovirus infection amplifies CD8 T-lymphocyte mobilisation and egress in response to exercise
James E. Turner et al.
BRAIN BEHAVIOR AND IMMUNITY (2010)
Dasatinib 100 mg Once Daily Minimizes the Occurrence of Pleural Effusion in Patients With Chronic Myeloid Leukemia in Chronic Phase and Efficacy Is Unaffected in Patients who Develop Pleural Effusion
Kimmo Porkka et al.
CANCER (2010)
Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy
Peter Rohon et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
The BCR/ABL-inhibitors Imatinib, Nilotinib and Dasatinib differentially affect NK cell reactivity
Julia Salih et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion
Yasunobu Nagata et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
Selective Mobilization of Cytotoxic Leukocytes by Epinephrine
Stoyan Dimitrov et al.
JOURNAL OF IMMUNOLOGY (2010)
Lck is a key target of imatinib and dasatinib in T-cell activation
K. C. Lee et al.
LEUKEMIA (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Large-scale data integration framework provides a comprehensive view on glioblastoma multiforme
Kristian Ovaska et al.
GENOME MEDICINE (2010)
A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34)
Satu Mustjoki et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia
Dong Hwan Kim et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
F. J. Giles et al.
LEUKEMIA (2009)
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
S. Mustjoki et al.
LEUKEMIA (2009)
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia
Kimmo Porkka et al.
BLOOD (2008)
The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro
Stephen Blake et al.
CLINICAL IMMUNOLOGY (2008)
EphA and ephrin-A proteins regulate integrin-mediated T lymphocyte interactions
Nigel Sharfe et al.
MOLECULAR IMMUNOLOGY (2008)
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
A. Hochhaus et al.
LEUKEMIA (2008)
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
J. Cortes et al.
LEUKEMIA (2008)
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib, reveal novel kinase and nonkinase targets
Uwe Rix et al.
BLOOD (2007)
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure
Alfonso Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Marcus Bantscheff et al.
NATURE BIOTECHNOLOGY (2007)
The Btk tyrosine kinase is a major target of the Bcr-Abi inhibitor dasatinib
Oliver Hantschel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Phase I trial of intermittent administration of sorafenib (BAY 43-9006) for patients (pts) with refractory/relapsed acute myelogenous leukemia (AML)
A. Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure
Feng R. Luo et al.
CLINICAL CANCER RESEARCH (2006)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Granulocyte transmigration through the endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1)
K Koskinen et al.
BLOOD (2004)
Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: A novel pathway for immune response amplification
S Danese et al.
JOURNAL OF IMMUNOLOGY (2004)
CLEVER-1 mediates lymphocyte transmigration through vascular and lymphatic endothelium
M Salmi et al.
BLOOD (2004)
Diverse roles of Eph receptors and ephrins in the regulation of cell migration and tissue assembly
A Poliakov et al.
DEVELOPMENTAL CELL (2004)
Mechanisms and functions of EPH and ephrin signalling
K Kullander et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
c-Src tyrosine kinase binds the β2-adrenergic receptor via phospho-Tyr-350, phosphorylates G-protein-linked receptor kinase 2, and mediates agonist-induced receptor desensitization
GF Fan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
